Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of the Dopaminergic and Glutamatergic Systems, and a Serotonin Reuptake Inhibitor - ResearchAndMarkets.com

May 16, 2018

DUBLIN--(BUSINESS WIRE)--May 16, 2018--The “Drug Overview: lumateperone” report has been added to ResearchAndMarkets.com’s offering.

Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulator of the dopaminergic and glutamatergic systems, and a serotonin reuptake inhibitor. By targeting the serotonergic and dopaminergic systems, the drug appears to reduce agitation and minimize positive symptoms. Its additional actions on glutamatergic signaling are believed to help address both negative and cognitive schizophrenia symptoms.

Intra-Cellular Therapies licensed lumateperone from its original developer, Bristol-Myers Squibb, in 2005, and is now solely responsible for the drug’s development. In December 2015, the company announced the initiation of patient enrollment for its two Phase III trials in bipolar depression. Additional clinical programs with lumateperone include its Phase III development in schizophrenia and behavioral disturbances in dementia.

Key Topics Covered

Drug Overview Product Profiles lumateperone: Bipolar Disorder lumateperone: Schizophrenia

List of Figures

Figure 1: Lumateperone for bipolar disorder - SWOT analysis

Figure 2: Drug assessment summary for lumateperone in bipolar disorder

Figure 3: Drug assessment summary for lumateperone in bipolar disorder

Figure 4: Lumateperone for schizophrenia - SWOT analysis

Figure 5: Drug assessment summary of lumateperone for schizophrenia

Figure 6: Drug assessment summary of lumateperone for schizophrenia

Figure 7: Lumateperone sales for schizophrenia in the US, 2017-26

List of Tables

Table 1: Lumateperone drug profile

Table 2: Lumateperone Phase III trials in bipolar disorder

Table 3: Lumateperone drug profile

Table 4: Lumateperone Phase II and Phase III data in schizophrenia

Table 5: Lumateperone other interim Phase II data in schizophrenia

Table 6: Lumateperone sales for schizophrenia in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/fdlpbx/lumateperone?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005524/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/16/2018 05:00 AM/DISC: 05/16/2018 05:00 AM


Update hourly